Research progress on risk factors for poor response of ursodeoxycholic acid in primary biliary cholangitis / 中华肝脏病杂志
Chinese Journal of Hepatology
;
(12): 73-76, 2019.
Article
in Chinese
| WPRIM
| ID: wpr-810373
ABSTRACT
Primary biliary cholangitis (PBC) is an autoimmune-mediated chronic cholestatic liver disease. Ursodeoxycholic acid (UDCA) is a first-line drug approved by the Food and Drug Administration for the treatment of PBC. It can effectively improve serum biochemical indicators, delay histological progress, and prolong the survival of non-transplant patients. However, around 40% of patients with PBC have a poor response to UDCA with a poor outcome. Early identification of patients with poor biochemical responses and timely second-line treatment may alter the course of the disease. This article summarizes the risk factors for the poor response of UDCA in the PBC.
Full text:
Available
Index:
WPRIM (Western Pacific)
Type of study:
Etiology study
/
Prognostic study
/
Risk factors
Language:
Chinese
Journal:
Chinese Journal of Hepatology
Year:
2019
Type:
Article
Similar
MEDLINE
...
LILACS
LIS